Niagen Bioscience, Inc. — Director's Dealing 2010

May 25, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2010-05-20

Reporting Person: GERMAIN MARK (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	282100	Disposed	2020-05-20	Common Stock (282100)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	282100	Disposed	2020-05-20	Common Stock (282100)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	67500	Disposed	2020-05-20	Common Stock (67500)	Direct

Footnotes

F1: Options vest 50% over two years beginning on May 20, 2011.

F2: Options vest 50 over two years beginning on May 20, 2011; provided further that, these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certian Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrant have been exercised, then 25% of these options are exercisable; if 50% to 74.9% of such warrant have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable.

F3: Options vest 1/12 every month for twelve months and will be 100% vested May 20, 2011